Evaristo Nieto
Research Subjects
Evaristo Nieto has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Eduard Vieta
Hospital Clínic de Barcelona
12 shared publications - Diego Hidalgo-Mazzei
Universitat de Barcelona (UB)
4 shared publications - Maria Mur
Psychiatric Service, Hospital Santa Maria, University of Lleida, IRBLleida (Biomedicine Research Institute), Lleida, Spain
4 shared publications - Caterina Mar Bonnin
Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
3 shared publications - Francesc Colom
Mental Health Group, IMIM-Hospital del Mar, Barcelona, Catalonia, Spain
3 shared publications - Juan Undurraga
Clínica Alemana Universidad del Desarrollo
3 shared publications
Latest Publications
- Top Cited Papers
- 1 January 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 242, 111-122
Association between completed suicide and bipolar disorder: A systematic review of the literature
- 1 January 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 242, 111-122
Top Cited PapersAssociation between completed suicide and bipolar disorder: A systematic review of the literature
- 1 August 2015
- Published by Elsevier in Journal of Affective Disorders
- Vol. 182, 121-125
Predictors of functional outcome after a manic episode
- 1 August 2015
- Published by Elsevier in Journal of Affective Disorders
- Vol. 182, 121-125
Predictors of functional outcome after a manic episode
- 1 June 2015
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 30 (4) , 528-534
Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study
Background: Asenapine is the most recent compound that has been FDA- and EMA-approved for treatment of mania. Its efficacy and safety have been assessed in placebo-controlled trials, but little is known about its performance in routine clinical conditions. In this study, we compared features of patients treated with adjunctive asenapine or other adjunctive antipsychotics and the costs of the treatment.Methods: A combined prospective and retrospective data collection and analysis was conducted from January 2011 to December 2013 following a clinical interview and assessment of manic and depressive symptoms (YMRS, HDRS-17), clinical state (CGI-BP-M), psychosocial functioning (FAST), sexual dysfunction (PRSexDQ) and health resource costs associated with treatment with adjunctive asenapine versus other adjunctive antipsychotics.Results: Hundred and fifty-two patients from different university hospitals were included. Fifty-three patients received adjunctive asenapine and 99 received other adjunctive antipsychotics concomitantly to mood stabilizers. Considering inpatients, those treated with adjunctive asenapine presented a significantly less severe manic episode (P = 0.001), less psychotic symptoms (P = 0.030) and more comorbid personality disorder (P = 0.002). Regarding outpatients, those treated with adjunctive asenapine showed significantly less severe manic episode (P = 0.046), more previous mixed episodes (P = 0.013) and more sexual dysfunction at baseline (P = 0.036). No significant differences were found in mean total costs per day.Conclusion: Clinicians tended to use adjunctive asenapine in patients with less severe manic symptoms but more complex clinical profile, including more mixed episodes in the past, concomitant personality disorder, and sexual problems. Treatment with adjunctive asenapine was not associated with higher costs when compared to other options.
- 1 June 2015
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 30 (4) , 528-534
Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study
Background: Asenapine is the most recent compound that has been FDA- and EMA-approved for treatment of mania. Its efficacy and safety have been assessed in placebo-controlled trials, but little is known about its performance in routine clinical conditions. In this study, we compared features of patients treated with adjunctive asenapine or other adjunctive antipsychotics and the costs of the treatment.Methods: A combined prospective and retrospective data collection and analysis was conducted from January 2011 to December 2013 following a clinical interview and assessment of manic and depressive symptoms (YMRS, HDRS-17), clinical state (CGI-BP-M), psychosocial functioning (FAST), sexual dysfunction (PRSexDQ) and health resource costs associated with treatment with adjunctive asenapine versus other adjunctive antipsychotics.Results: Hundred and fifty-two patients from different university hospitals were included. Fifty-three patients received adjunctive asenapine and 99 received other adjunctive antipsychotics concomitantly to mood stabilizers. Considering inpatients, those treated with adjunctive asenapine presented a significantly less severe manic episode (P = 0.001), less psychotic symptoms (P = 0.030) and more comorbid personality disorder (P = 0.002). Regarding outpatients, those treated with adjunctive asenapine showed significantly less severe manic episode (P = 0.046), more previous mixed episodes (P = 0.013) and more sexual dysfunction at baseline (P = 0.036). No significant differences were found in mean total costs per day.Conclusion: Clinicians tended to use adjunctive asenapine in patients with less severe manic symptoms but more complex clinical profile, including more mixed episodes in the past, concomitant personality disorder, and sexual problems. Treatment with adjunctive asenapine was not associated with higher costs when compared to other options.
- 5 May 2015
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 49 (6) , 540-549
Making sense of DSM-5 mania with depressive features
The assessment of the depressive component during mania has become critical for the accurate diagnosis of mixed states, which were defined very narrowly in the past classification systems before Diagnostic and Statistical Manual of Mental Disorders (5th ed.). The aim of this study was to compare socio-demographic, clinical and therapeutic characteristics, as well as clinical and functional outcomes, between manic patients with and without mixed features to validate the relevance of the Diagnostic and Statistical Manual of Mental Disorders (5th ed.) mixed specifier. This is a subanalysis of a multicentre naturalistic study MANía Aguda y COnsumo de Recursos (acute mania and health resource consumption [MANACOR]) on the burden of mania in bipolar patients from four hospitals in Catalonia (Spain). The sample consisted of 169 adult patients presenting a manic episode and systematically assessed during a 6-month period. A total of 27% (n = 46/169) of manic patients showed mixed features. Total number of episodes (p = 0.027), particularly depressive and mixed, was greater in manic patients with mixed features, as well as depressive onset (p = 0.018), suicide ideation (p = 0.036), rapid cycling (p = 0.035) and personality disorders (p = 0.071). In contrast, a higher percentage of pure manic subjects were inpatients (p = 0.035), started the illness with mania (p = 0.018) and showed family history of bipolar disorder (p = 0.037), congruent psychotic symptoms (p = 0.001) and cannabis use (p = 0.006). At baseline, pure manic patients received more risperidone (p = 0.028), while mixed patients received more valproate (p = 0.049) and antidepressants (p = 0.005). No differences were found in syndromic recovery at the end of the study. However, depressive change was higher in the mixed group (p = 0.010), while manic change was higher in the pure manic group (p = 0.029). At the end of follow-up, the group with mixed features showed a significant trend towards higher psychosocial dysfunction. A total of 27% of manic patients showed mixed features. Groups differed regarding clinical characteristics, course of illness, psychosocial functioning, prescribed treatment and symptom progress. Depressive symptoms in mania should be routinely assessed and considered to guide treatment.
- 5 May 2015
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 49 (6) , 540-549
Making sense of DSM-5 mania with depressive features
The assessment of the depressive component during mania has become critical for the accurate diagnosis of mixed states, which were defined very narrowly in the past classification systems before Diagnostic and Statistical Manual of Mental Disorders (5th ed.). The aim of this study was to compare socio-demographic, clinical and therapeutic characteristics, as well as clinical and functional outcomes, between manic patients with and without mixed features to validate the relevance of the Diagnostic and Statistical Manual of Mental Disorders (5th ed.) mixed specifier. This is a subanalysis of a multicentre naturalistic study MANía Aguda y COnsumo de Recursos (acute mania and health resource consumption [MANACOR]) on the burden of mania in bipolar patients from four hospitals in Catalonia (Spain). The sample consisted of 169 adult patients presenting a manic episode and systematically assessed during a 6-month period. A total of 27% (n = 46/169) of manic patients showed mixed features. Total number of episodes (p = 0.027), particularly depressive and mixed, was greater in manic patients with mixed features, as well as depressive onset (p = 0.018), suicide ideation (p = 0.036), rapid cycling (p = 0.035) and personality disorders (p = 0.071). In contrast, a higher percentage of pure manic subjects were inpatients (p = 0.035), started the illness with mania (p = 0.018) and showed family history of bipolar disorder (p = 0.037), congruent psychotic symptoms (p = 0.001) and cannabis use (p = 0.006). At baseline, pure manic patients received more risperidone (p = 0.028), while mixed patients received more valproate (p = 0.049) and antidepressants (p = 0.005). No differences were found in syndromic recovery at the end of the study. However, depressive change was higher in the mixed group (p = 0.010), while manic change was higher in the pure manic group (p = 0.029). At the end of follow-up, the group with mixed features showed a significant trend towards higher psychosocial dysfunction. A total of 27% of manic patients showed mixed features. Groups differed regarding clinical characteristics, course of illness, psychosocial functioning, prescribed treatment and symptom progress. Depressive symptoms in mania should be routinely assessed and considered to guide treatment.
- 1 April 2015
- Published by Elsevier in Revista de Psiquiatría y Salud Mental
- Vol. 8 (2) , 55-64
Los costos y consumo de recursos sanitarios asociados a episodios maníacos en la práctica clínica diaria: el estudio MANACOR
- 1 April 2015
- Published by Elsevier in Revista de Psiquiatría y Salud Mental
- Vol. 8 (2) , 55-64
Los costos y consumo de recursos sanitarios asociados a episodios maníacos en la práctica clínica diaria: el estudio MANACOR
- 1 January 2008
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 9 (3) , 219-224
A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone
Risperidone is the first atypical antipsychotic to become available in a long-acting, injectable formulation. This is the first prospective study to assess the effectiveness of long-acting risperidone in a cohort of bipolar patients. Twenty-nine DSM-IV acutely manic bipolar inpatients with a history of poor or partial adherence to medication entered the mirror-design observational study. They received naturalistic treatment for a manic episode plus long-acting, injectable risperidone for a mean period of 2 years. The following measures were used to assess the effectiveness of risperidone: the number of hospitalizations, the number of manic, mixed, and depressive episodes leading to hospitalization, the mean duration of hospitalizations, time to relapse, treatment adherence, aggression and suicide attempts. The Clinical Global Impressions (CGI) was used for clinical relevance as well. During the follow-up, there was a significant decrease in the number of hospitalizations per patient (Z-2.72 P < 0.006), in the number of manic or mixed episodes leading to hospitalization (Z-2.68 P < 0.007) but not in the hospitalizations due to depressive episodes, a decrease in the average length of hospitalization per patient (Z-3.27 P < 0.001), a significant increase in the time to any new episode (first relapse) (Z-3.28, P < 0.001), and significant improvements in treatment adherence (P < 0.0001) and hetero-aggressive episodes (P < 0.0001), but not suicide attempts (P = NS). At study endpoint 14 patients (48%) were very much improved according to the CGI. This observational long-term study provides support to long-acting injectable risperidone being effective for the maintenance treatment of mania and improving treatment adherence, reducing relapses and re-hospitalization rates.
- 1 January 2008
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 9 (3) , 219-224
A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone
Risperidone is the first atypical antipsychotic to become available in a long-acting, injectable formulation. This is the first prospective study to assess the effectiveness of long-acting risperidone in a cohort of bipolar patients. Twenty-nine DSM-IV acutely manic bipolar inpatients with a history of poor or partial adherence to medication entered the mirror-design observational study. They received naturalistic treatment for a manic episode plus long-acting, injectable risperidone for a mean period of 2 years. The following measures were used to assess the effectiveness of risperidone: the number of hospitalizations, the number of manic, mixed, and depressive episodes leading to hospitalization, the mean duration of hospitalizations, time to relapse, treatment adherence, aggression and suicide attempts. The Clinical Global Impressions (CGI) was used for clinical relevance as well. During the follow-up, there was a significant decrease in the number of hospitalizations per patient (Z-2.72 P < 0.006), in the number of manic or mixed episodes leading to hospitalization (Z-2.68 P < 0.007) but not in the hospitalizations due to depressive episodes, a decrease in the average length of hospitalization per patient (Z-3.27 P < 0.001), a significant increase in the time to any new episode (first relapse) (Z-3.28, P < 0.001), and significant improvements in treatment adherence (P < 0.0001) and hetero-aggressive episodes (P < 0.0001), but not suicide attempts (P = NS). At study endpoint 14 patients (48%) were very much improved according to the CGI. This observational long-term study provides support to long-acting injectable risperidone being effective for the maintenance treatment of mania and improving treatment adherence, reducing relapses and re-hospitalization rates.
- 25 September 2002
- Published by Wiley in Bipolar Disorders
- Vol. 4 (5) , 335-340
Quetiapine in the treatment of rapid cycling bipolar disorder
Vieta E, Parramon G, Padrell E, Nieto E, Martinez‐Arán A, Corbella B, Colom F, Reinares M, Goikolea JM, Torrent C. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002: 4: 335–340. © Blackwell Munksgaard, 2002 Introduction: This prospective open‐label study assessed the impact of add‐on quetiapine in the treatment of rapid cycling bipolar patients. Methods: Fourteen rapid cycling bipolar patients were treated with quetiapine, which was added to their ongoing medication regimen for 112 ± 33 days. At the beginning of the study, five were manic, three were in a mixed state, three were depressed, two hypomanic and one was euthymic. Patients were assessed prospectively with a modified version of the Clinical Global Impression Scale for Bipolars (CGI‐BP), the Young Scale for mania (YMRS) and the Hamilton Scale for Depression (HDRS). Results: A significant reduction of the following scale scores was observed:• a 1.8 point reduction for the general CGI‐BP (p=0.013),• a –1.3 point for the mania subscale (p=0.016),• a –1.01 point for the YMRS (p=0.025).Improvement in depressive symptoms was not significant, neither in the CGI‐BP (–1 point, p=0.074) nor in the HDRS (–5.2 points, p=NS). The most common side‐effect was sedation (n=6, 43%). Doses of quetiapine were significantly reduced by the end of the study (443 ± 235 mg/day versus 268 ± 190 mg/day, p=0.008) and they also differed according to the initial episode to be treated (720 ± 84 mg/day for mania, and 183 ± 29 mg/day for depression, p=0.023). Conclusions: Quetiapine could possibly be an effective treatment for rapid cycling bipolar patients. Adequate doses for acute episodes could significantly differ according to the episode polarity and the length of treatment.
- 25 September 2002
- Published by Wiley in Bipolar Disorders
- Vol. 4 (5) , 335-340
Quetiapine in the treatment of rapid cycling bipolar disorder
Vieta E, Parramon G, Padrell E, Nieto E, Martinez‐Arán A, Corbella B, Colom F, Reinares M, Goikolea JM, Torrent C. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002: 4: 335–340. © Blackwell Munksgaard, 2002 Introduction: This prospective open‐label study assessed the impact of add‐on quetiapine in the treatment of rapid cycling bipolar patients. Methods: Fourteen rapid cycling bipolar patients were treated with quetiapine, which was added to their ongoing medication regimen for 112 ± 33 days. At the beginning of the study, five were manic, three were in a mixed state, three were depressed, two hypomanic and one was euthymic. Patients were assessed prospectively with a modified version of the Clinical Global Impression Scale for Bipolars (CGI‐BP), the Young Scale for mania (YMRS) and the Hamilton Scale for Depression (HDRS). Results: A significant reduction of the following scale scores was observed:• a 1.8 point reduction for the general CGI‐BP (p=0.013),• a –1.3 point for the mania subscale (p=0.016),• a –1.01 point for the YMRS (p=0.025).Improvement in depressive symptoms was not significant, neither in the CGI‐BP (–1 point, p=0.074) nor in the HDRS (–5.2 points, p=NS). The most common side‐effect was sedation (n=6, 43%). Doses of quetiapine were significantly reduced by the end of the study (443 ± 235 mg/day versus 268 ± 190 mg/day, p=0.008) and they also differed according to the initial episode to be treated (720 ± 84 mg/day for mania, and 183 ± 29 mg/day for depression, p=0.023). Conclusions: Quetiapine could possibly be an effective treatment for rapid cycling bipolar patients. Adequate doses for acute episodes could significantly differ according to the episode polarity and the length of treatment.
- 1 August 2000
- Published by Elsevier in Journal of Affective Disorders
- Vol. 59 (2) , 159-164
Alpha-1-acid glycoprotein in major depressive disorder
- 1 August 2000
- Published by Elsevier in Journal of Affective Disorders
- Vol. 59 (2) , 159-164
Alpha-1-acid glycoprotein in major depressive disorder
- 1 November 1998
- Published by Elsevier in Biological Psychiatry
- Vol. 44 (9) , 927-929
Recurrent brief depression successfully treated with lithium
- 1 November 1998
- Published by Elsevier in Biological Psychiatry
- Vol. 44 (9) , 927-929
Recurrent brief depression successfully treated with lithium
- 1 June 1997
- Published by Wolters Kluwer Health in Journal of Nervous & Mental Disease
- Vol. 185 (6) , 407-409
Suicidal Behavior in Bipolar I and Bipolar II Disorder
- 1 June 1997
- Published by Wolters Kluwer Health in Journal of Nervous & Mental Disease
- Vol. 185 (6) , 407-409
Suicidal Behavior in Bipolar I and Bipolar II Disorder